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Abstract
Introduction: The PACS01 trial has demonstrated that a docetaxel addition to adjuvant anthracycline-based
chemotherapy improves disease-free survival (DFS) and overall survival of node-positive early breast cancer (EBC).
We searched for prognostic and predictive markers for docetaxel’s benefit.
Methods: Tumor samples from 1,099 recruited women were analyzed for the expression of 34 selected proteins
using immunohistochemistry. The prognostic and predictive values of each marker and four molecular subtypes
(luminal A, luminal B, HER2-overexpressing, and triple-negative) were tested.
Results: Progesterone receptor-negativity (HR = 0.66; 95% CI 0.47 to 0.92, P = 0.013), and Ki67-positivity (HR = 1.53;
95% CI 1.12 to 2.08, P = 0.007) were independent adverse prognostic factors. Out of the 34 proteins, only Ki67-
positivity was associated with DFS improvement with docetaxel addition (adjusted HR = 0.51, 95% CI 0.33 to 0.79
for Ki67-positive versus HR = 1.10, 95% CI 0.75 to 1.61 for Ki67-negative tumors, P for interaction = 0.012). Molecular
subtyping predicted the docetaxel benefit, but without providing additional information to Ki67 status. The luminal
A subtype did not benefit from docetaxel (HR = 1.16, 95% CI 0.73 to 1.84); the reduction in the relapse risk was
53% (HR = 0.47, 95% CI 0.22 to 1.01), 34% (HR = 0.66, 95% CI 0.37 to 1.19), and 12% (HR = 0.88, 95% CI 0.49 to
1.57) in the luminal B, HER2-overexpressing, and triple-negative subtypes, respectively.
Conclusions: In patients with node-positive EBC receiving adjuvant anthracycline-based chemotherapy, the most
powerful predictor of docetaxel benefit is Ki67-positivity.
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Introduction
The use of adjuvant chemotherapy has improved prog-
nosis of early breast cancer [1]. Benefits in terms of
survival, first demonstrated in the 1970s with the CMF
(cyclophosphamide, methotrexate, fluorouracil) regi-
men, were improved with the addition of anthracycline
in the 1980s [2]. Recently, third-generation regimens,
based on the addition of taxane, were shown as even
more efficient [3].
However, patients do not benefit equally from the
same drugs and regimens. Current histo-clinical prog-
nostic factors and the factors predictive for response to
a given therapy are not sufficient to solve this heteroge-
neity, basing the choice of adjuvant chemotherapy regi-
m e nu p o nt h er i s k so fr e l a p s ea n dt o x i c i t y ,
comorbidities and physician’s experience, rather than
upon the probability of efficiency. Today, no factor pre-
dictive for efficiency of third-generation regimens has
been validated, and all node-positive patients empirically
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taxane [3], although the optimal role for taxanes in this
setting remains controversial. The 20 first-generation
taxane trials reported to date that compared taxane-
based versus taxane-free adjuvant regimens [4-22] and
three meta-analyses [23-25] have shown that the taxane-
associated absolute benefit is modest, that is, a mere 5%
for disease-free survival (DFS) and 3% for overall survi-
val (OS). Taxanes are associated with many side effects
and with greater deterioration of quality of life [26].
They are expensive and data are scarce regarding their
long-term toxicity. Meta-analyses of first-generation tax-
ane trials have shown that the DFS benefit associated
with taxane addition is independent of age and meno-
pausal status, degree of node involvement, estrogen
receptor (ER) expression, type of taxane and schedule of
administration [24]. In the absence of clear guidance on
which patients may benefit from taxanes, their inclusion
in adjuvant regimens has also been advocated as a
means to reduce exposure to anthracyclines and the risk
of associated late toxicity. Furthermore, the type of tax-
ane (docetaxel or paclitaxel), dose and schedule are still
debated. Today, an important question is whether sub-
groups of patients benefit more or less from taxanes in
the adjuvant setting. This benefit likely depends upon
molecular determinants that remain to be defined.
Randomized clinical trials provide an opportunity for
identifying such predictive biomarkers in the adjuvant
setting. To date, only immunohistochemistry (IHC)-
based studies have been retrospectively reported. Five of
them analyzed one to four markers (including ER, pro-
gesterone receptor (PR), HER2, and/or Ki67) in a series
ranging from 798 to 3,329 tumor samples [9,18,27-31].
A few data suggest that taxanes might benefit ER-nega-
tive and/or HER2-positive and/or luminal B breast can-
cer patients [9,28,29], but results are inconsistent,
notably with a recent study [32], negative for 15 proteins
analyzed in 1,350 samples.
The PACS01 trial was a multicenter, prospective, ran-
domized, phase III, open-label trial comparing six cycles
of fluorouracil, epirubicin (100 mg/m
2), and cyclopho-
sphamide (FEC) with three cycles of FEC followed by
three cycles of docetaxel (100 mg/m
2; FEC-D), as adju-
vant chemotherapy in node-positive operable breast can-
cer [8]. A total of 1,999 patients were enrolled between
1997 and 2000. With a median follow-up of 60 months,
the five-year DFS was 73% with FEC and 78% with FEC-
D (18% reduction in the relative risk of relapse). In an
analysis restricted to ER-positive tumors, Ki67 expres-
sion identified a subgroup of patients who could benefit
from docetaxel [30]. Here, we have analyzed the expres-
sion of 34 selected IHC markers in a subset of 1,099
patients included in the trial, regardless of their ER sta-
tus. Our objective was to assess the prognostic and/or
predictive value of these markers and the molecular sub-
types for the benefit of docetaxel in terms of DFS.
Materials and methods
Patients
This biomarker study is ancillary to the PACS01 trial. A
tumor block representative of the primary tumor was
collected for 1,190 out of the 1,999 enrolled patients. All
samples were obtained from operated tumors before any
systemic therapy. Patients provided written informed
consent for research use, and the study was approved by
the ethics committee/institutional review board. Post-
menopausal women with hormone receptor (HR)-posi-
tive tumors (ER and/or PR-positive) received tamoxifen
after completion of chemotherapy. In December 1998,
the protocol was amended to require tamoxifen for pre-
menopausal women with HR-positive disease. Radiother-
apy was mandatory for all patients who had undergone
breast-conservative surgery, and was recommended after
mastectomy. No patient with an HER2-positive tumor
received trastuzumab in the adjuvant setting. The pri-
mary end-point was DFS, defined as the time from ran-
domization until the first event: relapse (local, regional,
or metastatic), contralateral breast cancer, or death from
any cause.
For translational studies, the 1,190 tumors had been
centrally immunostained with ER, PR, Ki67 and HER2
specific antibodies on standard slides [30]. Here, we
considered ER and PR staining as positive when at least
1% of tumor cells were stained. For Ki67, the positivity
cut-off value was 20%. The HER2 status was evaluated
with the Dako scale (HercepTest kit scoring guidelines,
DakoCytomation, Copenhagen, Denmark): positivity cor-
responded to 3+ IHC score, or 2+ score with Fluores-
cent In Situ Hybridisation (FISH) amplification. FISH
results were obtained from the previously reported cen-
tralized reading on standard slides [30]; a HER2/CEP17
ratio higher than 2.2 defined amplification. From the
1,190 cases, a tissue microarray (TMA) was prepared for
1,099 cases. Histo-clinical characteristics and magnitude
of docetaxel efficacy in the study group were similar to
those of the whole population of the trial (Additional
file 1, Table S1), suggesting its representativity. Histo-
clinical features of patients whose tumor samples were
and were not centrally tested were similar (data not
shown).
Tissue microarrays and immunohistochemistry
Tissue microarrays (TMAs) were prepared as previously
described from formalin-fixed and paraffin-embedded
tissues [33]. For each tumor, three representative areas
were selected from a hematoxylin-eosin-safran stained
section of a donor block. Core cylinders with a diameter
of 0.6 mm each were punched from each of these areas
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blocks using a specific arraying device (Alphelys, Plaisir,
France). Five-μms e c t i o n so ft h er e s u lting microarray
blocks were made and used for IHC after transfer to
glass slides.
The selection of the 30 additional proteins to be tested
was based on known or putative importance in breast
cancer as prognostic/predictive markers or in resistance
to taxane, and availability and suitability of a corre-
sponding antibody for paraffin-embedded tissues. They
explored different pathways: cell differentiation and
adhesion (Cytokeratins CK5/6, CK8/18, CK14, P-Cad-
herin, E-Cadherin, a-Catenin, b-Catenin, Afadin/AF6,
Mucin MUC1, Caveolin CAV1, Moesin, CD10, CD44),
proliferation and cell cycle (Aurora A, TACC2, TACC3,
Cyclin D1, P21, P27), ER-associated (GATA3), tyrosine
kinase signaling (EGFR, FGFR1, MET), apoptosis
(BCL2), checkpoints and tumor suppression (P53,
PTEN, FHIT), and others (Angiogenin, Topoisomerase
II a TOPO2A, microtubule-associated protein TAU).
Immunohistochemical analysis on TMA sections was
done as previously described [33] using Dako LSAB
R2
Kit in the autoimmunostainer (Dako Autostainer,
Glostrup, Denmark). Sections were deparaffinized in
Histolemon (Carlo Erba Reagenti, Rodano, Italy) and
rehydrated in graded ethanol solutions. Details of anti-
bodies are given in Additional file 2 (Table S2). The
dilution of each antibody was established on the basis of
negative and positive controls and staining with a range
of dilutions. For each antibody, the selected titer was in
the linear range and allowed the extinction of the nega-
tive control and the persistence of the positive control.
Results were evaluated by two pathologists (JJ, ECJ)
under a light microscope with the Spot Browser system
(Alphelys, Plaisir, France). Only invasive tumor compo-
nents were scored, using the quick score (QS, range
from 0 to 300). For each tumor, the mean of the score
of a minimum of two core biopsies was calculated. For
each antibody, a tumor was considered as positive when
the QS was superior to 0.
Statistical analysis
Distributions of molecular markers and other categorical
histo-clinical variables were compared between groups
using the Chi
2 test. The primary end-point was that of
the PACS01 trial, DFS, as defined above. Data concern-
ing patients without any event at last follow-up were
censored. The follow-up was calculated from the date of
randomization to the time of the first event or time of
last follow-up for censored patients. Survival curves
were derived from Kaplan-Meier estimates and com-
pared by log-rank test. Uni- and multivariate analyses
were done using Cox regression analysis. The variables
tested in univariate analyses included patients’ age,
pathological tumor size, number of pathologically
involved axillary lymph nodes, Scarff-Bloom Richardson
(SBR) grade, and IHC status of the 34 tested markers.
T h ep r o g n o s t i ci n f l u e n c eo fmarkers and IHC-defined
molecular subtypes was assessed in multivariate analysis
by the Cox proportional hazard models, using the
adjustment variables preplanned for the PACS01 trial:
age, number of pathologically involved axillary lymph
nodes, pathological tumor size, SBR grade, and HR sta-
tus, and the therapeutic arm. The predictive value of
each marker and molecular subtype for the docetaxel
benefit was assessed using a Cox regression model with
terms for treatment by marker interaction, with and
without adjustment with the variables quoted above.
Survival rates and hazard ratios (HR) are presented with
their 95% confidence intervals (95% CI). Statistical tests
were two-sided at the 5% level of significance without
adjustment for multiple comparisons. All analyses were
done using SAS Version 9.1 (Evry-Grégy-sur-Yerres,
France). The paper is written in accordance with report-
ing recommendations for tumor marker prognostic stu-
dies (REMARK) criteria.
Results
Patients’ characteristics and survival
Out of the 1,099 cases included in our analysis, 546 had
been treated in the FEC arm and 553 in the FEC-D
arm. Patients’ characteristics were balanced between the
two treatment arms, except for the pathological tumor
size, more frequently inferior to 20 mm in the FEC-D
arm as observed in the PACS01 trial (Table 1). Almost
all treated patients received radiotherapy. Tamoxifen use
was not different between arms, in both pre- and post-
menopausal women. The median follow-up was 60
months. The five-year DFS was 76% (95% CI 73.7 to
78.9). A total of 268 events were reported during the
study period, 150 in the FEC arm (27%) and 118 in the
FEC-D arm (21%). Respective five-year DFS was 72%
(95% CI 68.1 to 76.0) and 79% (95% CI 76.1 to 83.0; P=
0.0125, log-rank test; Figure 1). In multivariate analysis
(Additional file 3, Table S3), the features associated with
shorter DFS (Wald test) were age inferior to 50 years
(HR = 1.31), more than three involved axillary lymph
nodes (HR = 1.94): pathological tumor size superior or
equal to 20 mm (HR = 1.78), SBR grade superior to 1
(HR = 1.77 for grade 2, HR = 2.46 for grade 3), and
negative hormone receptor status (HR = 1.76), validating
the pre-planned choice of these variables as adjustment
variables for multivariate analyses. The adjusted HR for
an event associated with docetaxel was 0.78 (95% CI
0.60 to 1.02, P = 0.066, Wald test), similar to that
observed in the whole PACS01 trial.
In most of the subgroups defined according to these
histo-clinical prognostic features (age, lymph nodes, size,
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of relapse, with significantly greater benefit in patients
aged 50 years or older, pathological tumor size inferior
to 20 mm, four or more positive lymph nodes, and
negative HR status (data not shown). However, in multi-
variate analysis, none of these features showed signifi-
cant interaction with the chemotherapy arm (Additional
file 4, Figure S1).
Protein markers, survival and docetaxel benefit
The expression of 34 proteins in tumor samples was cen-
trally analyzed by IHC: ER, PR, Ki67 and HER2 on
standard slides, and the 30 additional proteins on TMAs.
Results are detailed in Table 2. Staining was heteroge-
neous between tumors. The percent of positive tumors
varied from 12.5% for Moesin to 98% for CK8/18.
Table 2 reports the correlation between each single
marker and DFS. The 12 proteins associated with
shorter DFS in univariate analysis (negativity of BCL2,
CK8/18, ER, GATA3, MUC1, PR, and TAU, and positiv-
ity of Aurora A, HER2, Ki67, P-Cadherin, and P53) were
included in multivariate analysis, together with pre-
planned histo-clinical variables. The status of two pro-
teins remained associated with shorter DFS (Wald test):
PR-negativity (HR = 0.66; 95% CI 0.47 to 0.92, P =
0.013), and Ki67-positivity (HR = 1.53; 95% CI 1.12 to
2.08, P = 0.007).
We then searched for an association between each
protein and the benefit of docetaxel in terms of DFS.
Results of univariate and multivariate analyses are
detailed in Additional file 5, Table S4. On multivariate
analysis (Table 3 and Figure 2), the addition of docetaxel
reduced the risk of an event (HR for relapse inferior to
1) in most of the subgroups defined by the positive sta-
tus and the negative status of most of the 34 proteins,
significantly (P <0.05) for 11 proteins (Angiogenin, b-
Catenin, CAV1, CD44, E-Cadherin, CK8/18, Ki67, MET,
MUC1, P27, and PTEN). However, an interaction
between the protein expression and the addition of doc-
etaxel was significant only for Ki67 (P =0 . 0 1 2 ) .D o c e -
taxel was associated with a 49% reduction in the risk of
an event (HR = 0.51, 95% CI 0.33 to 0.79; P =0 . 0 0 3
Wald test) in Ki67-positive patients (Figure 3A), but
with no reduction (HR = 1.10 95% CI 0.75 to 1.61; P =
0.612) in Ki67-negative patients (Figure 3B). Interaction
of borderline significance (P ≤0.15) was observed for
Table 1 Characteristics of patients in this substudy
according to the treatment
Characteristic FEC
(N = 546)
FEC-D
(N = 553)
P-value
Age 0.794
<50 years 261 (47.8%) 260 (47.0%)
≥50 years 285 (51.2%) 293 (53.0%)
Menopausal status 0.770
Premenopausal 332 (61.8%) 331 (61.0%)
Postmenopausal 214 (38.2%) 222 (39.0%)
Surgery
Breast conservation 313 (57.3%) 342 (61.8%) 0.127
Modified mastectomy 233 (42.7%) 211 (38.2%)
Pathological tumor size (pT)
<2 cm 163 (32.2%) 200 (39.9%) 0.039
2 ≤pT <-5 cm 306 (60.5%) 269 (53.7%)
≥5 cm 37 (7.3%) 32 (6.4%)
SBR Grade
I 52 (9.6%) 67 (12.2%) 0.288
II 231 (42.6%) 238 (43.2%)
III 237 (43.7%) 217 (39.4%)
Not gradable 22 (4.1%) 29 (5.3%)
Positive lymph nodes 329 (60.3%) 342 (61.8%) 0.589
1 to 3 217 (39.7%) 211 (38.2%)
≥4
Hormone receptors
Positive (ER and/or PR) 414 (78.0%) 419 (78.0%) 0.981
Negative (ER and PR) 117 (22.0%) 118 (22.0%)
Estrogen receptor
Positive 394 (74.2%) 391 (72.8%) 0.607
Negative 137 (25.8%) 146 (27.2%)
Progesterone receptor
Positive 276 (52.0%) 305 (56.7%) 0.122
Negative 255 (48.0%) 233 (43.3%)
HER2
Positive 93 (17.1%) 82 (15.0%) 0.337
Negative 451 (82.9%) 466 (85.0%)
DFS, event
Yes 150 (27%) 118 (21%) 0.021
No 396 (73%) 435 (79%)
Figure 1 Disease-free survival in patients included in this sub-
study. Kaplan-Meier DFS curves in patients treated without (FEC:
black curve) and with (FEC-D: dashed curve) docetaxel.
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Marker Category N
(%)
Univariate Multivariate
Unadjusted
Hazard Ratio
(95%CI)
P-value
(Log-rank)
Adjusted
Hazard Ratio
(95%CI)
P-value(Wald)
AF6 Neg. 193 (23%)
Pos. 656 (77%) 0.86 (0.63 to 1.20) 0.386 0.87 (0.61 to 1.24) 0.437
Angiogenin Neg. 71 (7%)
Pos. 879 (93%) 1.06 (0.65 to 1.74) 0.803 1.01 (0.59 to 1.75) 0.967
Aurora A Neg. 585 68%)
Pos. 276 (32%) 1.41 (1.07 to 1.87) 0.015 1.32 (0.98 to 1.79) 0.070
BCL2 Neg. 377 (39%)
Pos. 580 (61%) 0.60 (0.47 to 0.78) <.001 0.82 (0.60 to 1.12) 0.217
a-Catenin Neg. 359 42%)
Pos. 501 (58%) 0.88 (0.67 to 1.16) 0.374 0.99 (0.73 to 1.34) 0.927
b-Catenin Neg. 265 (29%)
Pos. 636 (71%) 0.83 (0.63 to 1.11) 0.216 0.88 (0.64 to 1.21) 0.439
CAV1 Neg. 179 (19%)
Pos. 778 (81%) 1.39 (0.96 to 1.99) 0.077 1.16 (0.76 to 1.76) 0.495
CD10 Neg. 409 (45%)
Pos. 508 (55%) 1.19 (0.91 to 1.55) 0.199 1.20 (0.90 to 1.61) 0.211
CD44 Neg. 430 (61%)
Pos. 280 (39%) 0.83 (0.62 to 1.14) 0.264 0.90 (0.65 to 1.25) 0.524
CK5/6 Neg. 248 (27%)
Pos. 667 (73%) 0.88 (0.67 to 1.18) 0.414 0.98 (0.71 to 1.36) 0.921
CK8/18 Neg. 22 (2%)
Pos. 948 (98%) 0.30 (0.17 to 0.55) <.001 0.54 (0.28 to 1.03) 0.060
CK14 Neg. 774 (83%)
Pos. 158 (17%) 1.01 (0.71 to 1.42) 0.974 0.81 (0.55 to 1.19) 0.288
Cyclin D1 Neg. 316 (33%)
Pos. 648 (67%) 0.86 (0.66 to 1.13) 0.301 1.11 (0.81 to 1.51) 0.526
E-Cadherin Neg. 128 (13%)
Pos. 873 (87%) 1.09 (0.74-1.60) 0.653 0.98 (0.62-1.57) 0.937
EGFR Neg. 814 (81%)
Pos. 185 (19%) 1.02 (0.74 to 1.41) 0.895 0.72 (0.49 to 1.05) 0.090
ER Neg. 283 (26%)
Pos. 785 (74%) 0.53 (0.42 to 0.69) <0.001 0.90 (0.47 to 1.71) 0.744
FGFR1 Neg. 114 (15%)
Pos. 626 (85%) 1.36 (0.86 to 2.14) 0.189 1.60 (0.93 to 2.74) 0.087
FHIT Neg. 237 (26%)
Pos. 672(74%) 1.03 (0.76 to 1.40) 0.825 1.41 (0.98 to 2.01) 0.062
GATA3 Neg. 166 (17%)
Pos. 816 (83%) 0.70 (0.52 to 0.96) 0.027 0.83 (0.58 to 1.19) 0.311
HER2 Neg. 917 (84%)
Pos. 175 (16%) 1.64 (1.23 to 2.19) <0.001 1.12 (0.80 to 1.57) 0.493
Ki67 Neg. 661 (70%)
Pos. 280 (30%) 1.97 (1.51 to 2.56) <0.001 1.53 (1.12 to 2.08) 0.007
MET Neg. 602 (66%)
Pos. 315 (34%) 1.26 (0.97 to 1.65) 0.088 1.25 (0.93 to 1.66) 0.134
Moesin Neg. 824 (87%)
Pos. 118 (13%) 1.31 (0.91 to 1.89) 0.145 1.95 (.63 to 1.44) 0.815
MUC1 Neg. 95 (9%)
Pos. 938 (91%) 0.59 (0.42 to 0.86) 0.005 0.77 (0.51 to 1.16) 0.213
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docetaxel benefit for patients with a marker-positive
tumor.
Molecular subtypes, survival and docetaxel benefit
Genomics has revealed at least four subtypes of breast
cancer: luminal A, luminal B, basal, and HER2/ERBB2-
overexpressing [34]. These s u b t y p e sm a yb ea p p r o x i -
mately, but more easily for clinical routine, defined by
four IHC markers (ER, PR, HER2, and Ki67). Based on
these markers, we classified the 1,099 samples into four
subtypes: luminal A (HR-positive, HER2-negative, Ki67-
negative: N = 525, 54%), luminal B (HR-positive, HER2-
negative, Ki67-positive; N = 125, 13%), HER2-overex-
pressing (HER2-positive, whatever HR; N = 175, 18%),
and triple-negative (HR-negative, HER2-negative; N =
148, 15%).
As expected, these subtypes correlated with histo-clin-
ical variables (Additional file 6, Table S5). Triple-nega-
tive tumors and HER2-overexpressing tumors were
more frequently grade 3 than luminal tumors (P
<0.0001), as were luminal B tumors when compared
with luminal A tumors. HER2-overexpressing tumors
presented more frequently more than three involved
axillary lymph nodes, followed by luminal B tumors,
then luminal A, then triple-negative tumors (P =0 . 0 1 5 ) .
Classical basal markers (CK14, EGFR, Moesin, P-Cad-
h e r i n ,P 5 3 ) ,w e r em o r ef r e q u e n t l yp o s i t i v ei nt r i p l e -
negative tumors (P ≤0.001). Five-year DFS was different
among the subtypes (P <0.0001, log-rank test): 83% for
luminal A (95% CI 79.4to 6.2), 73% for luminal B (95%
CI 63.8 to 79.8), 66% for HER2-overexpressing (95% CI
58.3 to 72.7), and 65% for triple-negative (95% CI 56.9
to 72.4).
The benefit of docetaxel was analyzed per subtype
(Additional file 7, Figure S2). Results of uni- and multi-
variate analyses are shown in Additional file 8, Table S6.
In multivariate analysis, docetaxel was associated with a
53% reduction in the risk of relapse in the luminal B
subtype (HR = 0.47, 95% CI 0.22 to 1.01; P =0 . 0 5 ,
Wald test), a 34% reduction in the HER2-overexpressing
subtype (HR = 0.66, 95% CI 0.37 to 1.19; P =0 . 1 4 ) ,a n d
a 12% reduction (HR = 0.88, 95% CI 0.49 to 1.57, P =
0.67) in the triple-negative subtype. By contrast, the risk
of an event was 16% higher with vs without docetaxel in
luminal A tumors (HR = 1.16, 95% CI 0.73 to 1.84, P =
0.52). The interaction between benefit of docetaxel and
each subtype was significant for luminal B (P = 0.047),
borderline for HER2-overexpressing (P = 0.14), and not
significant for triple-negative (P = 0.46).
We explored the added predictive value of molecular
subtyping compared with Ki67 status alone by testing the
interaction between the molecular subtype factor and the
treatment arm in a Cox model adjusted for the pre-
planned histo-clinical variables and Ki67 by treatment
interaction. Analysis using the likelihood ratio test did
not show any significant added predictive value to that
provided by the Ki67 status alone for DFS (P = 0.88).
Discussion
Identifying the patients who would and those who
would not benefit from taxanes is crucial to moving
Table 2 Univariate and multivariate analyses of 34 antibodies for DFS (Continued)
P21 Neg. 378 (41%)
Pos. 545 (59%) 0.93 (0.71 to 1.22) 0.616 0.84 (0.62 to 1.13) 0.241
P27 Neg. 175 (19%)
Pos. 768 (81%) 0.89 (0.65 to 1.24) 0.509 1.06 (0.75 to 1.50) 0.754
P53 Neg. 746 (75%)
Pos. 246 (25%) 1.59 (1.21 to 2.07) <.001 1.29 (0.95 to 1.75) 0.107
P-Cadherin Neg. 570 (61%)
Pos. 371 (39%) 1.44 (1.12 to 1.87) 0.005 1.31 (0.96 to 1.78) 0.089
PR Neg. 488 (46%)
Pos. 581 (54%) 0.54 (0.42 to 0.69) <0.001 0.66 (0.47 to 0.92) 0.013
PTEN Neg. 314 (34%)
Pos. 610 (66%) 1.00 (0.76 to 1.33) 0.977 1.00 (0.74 to 1.36) 0.991
TACC2 Neg. 148 (17%)
Pos. 723 (83%) 1.05 (0.73 to 1.52) 0.777 0.95 (0.64 to 1.42) 0.796
TACC3 Neg. 35 (6%)
Pos. 564 (94%) 1.83 (0.75 to 4.47) 0.179 1.17 (0.47 to 2.88) 0.738
TAU Neg. 685 (83%)
Pos. 141 (17%) 0.56 (0.36 to 0.88) 0.011 0.75 (0.47 to 1.21) 0.243
TOPO2A Neg. 199 (22%)
Pos. 714 (78%) 1.41 (0.99 to 2.00) 0.052 1.39 (0.93 to 2.07) 0.104
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analyzed the expression of 34 selected proteins in a sub-
set of 1,099 patients included in the PACS01 trial.
We show that a Ki67-positive status is not only inde-
pendently associated with shorter DFS, but also with the
benefit of a docetaxel addition in women treated with
adjuvant anthracycline-based chemotherapy. Ki67,
expressed during the cell cycle, is a well-established cell
proliferation marker. Its expression in breast cancer cor-
relates with poor prognosis [35,36] and higher response
to chemotherapy. In the neo-adjuvant setting, correla-
tion between Ki67 positivity and response to taxanes,
either as monotherapy [37] or in association with
anthracyclines [38], has been reported, although the
relationship was not observed in other small series
[39,40]. We found a prognostic correlation much more
important in docetaxel-free patients (P <0.001, log-rank
test) than in docetaxel-treated patients (P =0 . 0 4 8 ) ,i n
relation to the interaction observed with docetaxel bene-
fit. Such interaction has been previously studied in ran-
domized trials of adjuvant chemotherapy. Higher
efficiency of the CMF regimen vs. no chemotherapy (P
= 0.16 for interaction) was reported in Ki67-positive ER-
positive patients treated in the NSABP-20 trial [41],
whereas Ki67 labeling index was not predictive of better
response to adjuvant chemotherapy in endocrine-
responsive tumors [42]. Bartlett et al.a n a l y z e dd a t ao f
the UK NEAT/BR9601 trial, which showed benefit for
the addition of anthracyclines to CMF regimen, and did
not detect any interaction with anthracycline benefit for
Ki67 status [43]. The benefit of docetaxel (P =0 . 1 1f o r
Table 3 Multivariate analyses of 34 antibodies for
interaction with chemotherapy arm
Marker Category N
Arms A/B
Adjusted
Hazard ratio
(95% CI)
P-value
forinteraction
AF6 Neg. 99/94 0.94 (0.50 to 1.79) 0.663
Pos. 321/335 0.86 (0.61 to 1.23)
Angiogenin Neg. 34/37 1.68 (0.47 to 5.96) 0.1
Pos. 439/440 0.66 (0.49 to 0.89)
Aurora A Neg. 293/292 0.91 (0.62 to 1.33) 0.228
Pos. 135/141 0.61 (0.38 to 1.00)
BCL2 Neg. 184/193 0.78 (0.52 to 1.17) 0.905
Pos. 285/295 0.80 (0.54 to 1.19)
a-Catenin Neg. 177/182 0.85 (0.53 to 1.37) 0.875
Pos. 250/251 0.79 (0.53 to 1.16)
b-Catenin Neg. 123/142 1.19 (0.69 to 2.05) 0.14
Pos. 324/312 0.67 (0.47 to 0.96)
CAV1 Neg. 82/97 1.11 (0.50 to 2.44) 0.229
Pos. 389/389 0.69 (0.51 to 0.94)
CD10 Neg. 197/212 0.87 (0.55 to 1.38) 0.741
Pos. 259/249 0.77 (0.54 to 1.12)
CD44 Neg. 210/220 0.63 (0.41 to 0.96) 0.158
Pos. 128/152 1.03 (0.61 to 1.73)
CK5/6 Neg. 122/126 0.84 (0.48 to 1.48) 0.96
Pos. 332/335 0.79 (0.56 to 1.10)
CK8/18 Neg. 13/9 4.73 (0.96 to 23.3) 0.446
Pos. 468/480 0.69 (0.52 to 0.91)
CK14 Neg. 386/388 0.77 (0.56 to 1.05) 0.142
Pos. 84/74 0.41 (0.18 to 0.90)
Cyclin D1 Neg. 161/155 0.78 (0.48 to 1.26) 0.974
Pos. 317/331 0.78 (0.55 to 1.10)
E-Cadherin Neg. 62/66 1.77 (0.69 to 4.59) 0.154
Pos. 432/441 0.71 (0.53 to 0.95)
EGFR Neg. 401/413 0.85 (0.63 to 1.16) 0.235
Pos. 95/90 0.58 (0.30 to 1.13)
ER Neg. 137/146 0.79 (0.52 to 1.22) 0.976
Pos. 394/391 0.79 (0.56 to 1.10)
FGFR1 Neg. 56/58 0.32 (0.10 to 1.02) 0.178
Pos. 306/320 0.84 (0.59 to 1.19)
FHIT Neg. 127/110 0.00 (0.52 to 1.90) 0.473
Pos. 321/351 0.73 (0.52 to 1.01)
GATA3 Neg. 88/78 0.74 (0.40 to 1.37) 0.908
Pos. 407/409 0.74 (0.54 to 1.02)
HER2 Neg. 451/466 0.85 (0.63 to 1.15) 0.367
Pos. 93/82 0.65 (0.36 to 1.17)
Ki67 Neg. 327/334 1.10 (0.75 to 1.61) 0.012
Pos. 147/133 0.51 (0.33 to 0.79)
MET Neg. 301/301 0.91 (0.63 to 1.30) 0.154
Pos. 150/165 0.59 (0.38 to 0.94)
Moesin Neg. 412/412 0.77 (0.57 to 1.05) 0.92
Pos. 56/62 0.80 (0.39 to 1.65)
MUC1 Neg. 53/42 0.73 (0.32 to 1.70) 0.651
Pos. 461/477 0.73 (0.55 to 0.98)
P21 Neg. 187/191 0.74 (0.48 to 1.14) 0.879
Table 3 Multivariate analyses of 34 antibodies for inter-
action with chemotherapy arm (Continued)
Pos. 272/273 0.76 (0.51 to 1.13)
P27 Neg. 78/97 0.76 (0.41 to 1.42) 0.826
Pos. 378/390 0.73 (0.53 to 1.00)
P53 Neg. 364/382 0.76 (0.54 to 1.08) 0.74
Pos. 123/123 0.71 (0.45 to 1.13)
P-Cadherin Neg. 282/288 0.78 (0.52 to 1.17) 0.622
Pos. 179/192 0.68 (0.46 to 1.02)
PR Neg. 255/233 0.86 (0.61 to 1.22) 0.601
Pos. 276/305 0.76 (0.50 to 1.15)
PTEN Neg. 152/162 0.99 (0.60 to 1.64) 0.221
Pos. 315/295 0.68 (0.47 to 0.97)
TACC2 Neg. 70/78 0.54 (0.25 to 1.20) 0.397
Pos. 366/357 0.87 (0.63 to 1.19)
TACC3 Neg. 13/22 0.29 (0.04 to 2.14) 0.363
Pos. 284/280 0.97 (0.67 to 1.41)
TAU Neg. 340/345 0.83 (0.59 to 1.16) 0.611
Pos. 65/76 0.96 (0.38 to 2.42)
TOPO2A Neg. 104/95 0.82 (0.39 to 1.74) 0.917
Pos. 359/355 0.77 (0.56 to 1.06)
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Figure 2 Adjusted hazard ratios associated with docetaxel addition. Forest plots showing the adjusted hazard ratios associated with
docetaxel addition according to expression of 34 proteins.
B
Ki67-negative
A
Ki67-positive
Figure 3 Disease-free survival according to Ki67 status and docetaxel. A. Kaplan-Meier DFS curves in patients with Ki67-positive status
according to docetaxel addition. B. Similar to B, but in patients with Ki67-negative status.
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Page 8 of 14interaction) in Ki67-positive ER-positive patients
enrolled in the PACS01 trial has been reported [30].
Our present analysis, applied to all available PACS01
samples regardless of the ER status, showed a significant
interaction, with an adjusted HR for the risk of relapse
in Ki67-positive patients (HR = 0.51) equal to that pre-
viously reported for ER-positive patients only, and
superior to that observed in the unselected whole popu-
lation (HR = 0.81). By contrast, in an analysis of the
BCIRG001 trial [32], Ki67 did not present any interac-
tion with docetaxel benefit. In this study, the positivity
threshold was the median value of the tested population,
whereas we used the more classical 20% cut-off [36]. We
did not find in the literature any pre-clinical or clinical
data in the neo-adjuvant or the metastatic setting
regarding Ki67 status and the response to or the benefit
associated with docetaxel specifically. Of course, our
observations will require validation before application in
routine. But already, they clearly suggest that patients
with Ki67-positive breast cancer potentially derive a
high benefit from adjuvant docetaxel (adjusted HR =
0.51), and it might be a candidate for intensifying taxane
delivery (six cycles and/or a dose-dense scheme). By
contrast, we did not observe any additional benefit for
docetaxel in patients with Ki67-negative tumors
(adjusted HR = 1.10), who represent more than two-
thirds of the tested patients. A potential application
might be to omit docetaxel for these patients and go
back to six cycles of FEC. However, because that would
increase the risk of cardiotoxicity and leukemia, it is rea-
sonable to think that the delivery of three FEC three
docetaxel cycles would remain “as good” as six FEC
cycles and worthwhile giving. Whether Ki67 is mechan-
istically involved in the response to docetaxel remains to
be demonstrated, but even if it is not, it may be a mar-
ker of a phenotype more sensitive to docetaxel. One
may suppose that docetaxel, which exerts its cytotoxic
effects in the G2/M phase of the cycle by inhibiting the
microtubule disassembly (antimitotic effect), is more
active on rapidly proliferating cells (high Ki67).
We did not find any interaction among the 33 other
markers and docetaxel benefit. In fact, the relapse risk
was decreased by docetaxel addition in nearly all sub-
groups defined according to these markers, but without
significant difference for benefit between the marker-
positive and marker-negative subgroups. Univariate ana-
lysis showed higher reduction of risk in ER-negative
patients than in ER-positive ones, but the interaction
was not significant. Similar observation was reported in
the pooled analysis of two randomized trials [27], and
the analyses of BCIRG001 [32], NSABP-B28 [44],
CALGB9344 [45], and TACT [9] trials. Today, the pre-
dictive value of ER status for response to taxanes is not
demonstrated when considering ER alone, and
additional markers are required for identifying sub-
groups of ER-positive and ER-negative who most benefit
from these drugs. Our previous [30] and present data
suggest that Ki67 is a potential candidate. This predic-
tive value is also debated for HER2. We found a signifi-
cant interaction with HER2 status in univariate analysis,
with more benefit of docetaxel addition in HER2-posi-
tive patients (HR for relapse: 0.46 vs 0.84), but the inter-
action lost significance in multivariate analysis. Analysis
of two other adjuvant trials reported a benefit from the
addition of taxanes in HER2-positive patients [9,28],
with significant interaction in one [28], but analyses of
other trials yielded conflicting results [16,18,32,46].
Regarding the other markers, we observed a trend
towards a benefit from docetaxel in patients whose
tumor was positive for CK14, Angiogenin, and b-Cate-
nin, with a statistically borderline interaction, which
deserves further analysis in larger series.
More complex molecular combinations could prove
more informative than single markers for predicting
docetaxel benefit [9,29-31,47]. Here, we have defined
molecular subtypes according to the status of ER, PR,
HER2 and Ki67 proteins. These subtypes displayed
expected histo-clinical features. Notably, five-year DFS
was relatively good in the luminal A subtype, poor in
HER2-overexpressing and the triple-negative subtypes,
and intermediate in the luminal B subtype, in close
agreement with survival rates observed in the BCIRG001
[29] and GEICAM9906 trials [31], even if the definition
of luminal B and HER2-overexpressing subtypes was a
little different. Clearly, the subtype that did not benefit
from docetaxel in our series was luminal A, as reported
in the BCIRG001 trial [29], and for ER-positive, HER2-
negative tumors (assimilated to luminal A) in the
CALGB9344 [28] and TACT [9] trials. By contrast,
luminal A tumors unexpectedly benefited from pacli-
taxel in the GEICAM9906 trial [18]. The reasons for
discrepancy between this latter observation and the for-
mer ones are unclear, and longer follow-up is required.
The benefit we observed in the triple-negative tumors
(adjusted HR = 0.88) was not different from the benefit
observed in the whole-population, and interaction was
not significant. Two subtypes benefited from docetaxel
addition: luminal B and HER2-overexpressing. In lumi-
nal B patients, the absolute benefit in five-year DFS was
19% (DFS: 64% with FEC vs 83% with FEC-D); docetaxel
reduced the risk of relapse by 53% after adjustment for
histo-clinical variables, and the interaction was signifi-
cant. Similarly, luminal B BCIRG001 patients showed a
44% reduction of relapse risk with docetaxel [29]. This
was not confirmed in the GEICAM9906 sub-study [31],
which, however, used the same definition as the
BCIRG001 trial (HR-positive, and either Ki67-positive or
HER2-positive). In these two studies, the positivity cut-
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Ki67 (10% in the GEICAM9906, 13% in the BCIRG001
study). From literature data and our comparison of
luminal A vs luminal B tumors (Additional file 6, Table
S5), some biological features of luminal B vs luminal A
tumors might speculatively explain this differential bene-
fit from docetaxel: not only the higher proliferation rate
(Ki67), but also the lesser expression of BCL2 and TAU
whose expression has been associated with taxane resis-
tance [48,49], and the higher expression of P53, whose
mutations have been associated with resistance to DNA-
damaging agents such as anthracyclines [50], and rela-
tive sensitivity to taxanes [51]. However, none of these
markers, except Ki67, was associated with docetaxel
benefit in our univariate analysis (Additional file 5,
Table S4). Finally, docetaxel led to a 34% adjusted
reduction of the relapse risk (HR = 0.66) in the HER2-
overexpressing subtype, with a borderline interaction (P
= 0.14). No adjuvant trastuzumab was given in our ser-
ies, but it is likely that trastuzumab would not decrease
the observed docetaxel benefit. Significant interaction
between HER2, treatment and outcome was found in
the CALGB9344 trial, independently of ER status [28].
Higher benefit of taxanes was also reported in HER2-
positive, HR-negative BCIRG001 [29] and TACT [9]
patients, but not in the GEICAM9906 trial [31]. Because
the current IHC definition of luminal B and HER2-over-
expressing subtypes is not consensual, we repeated ana-
lyses using definitions used by others in the BCIRG001
[29] and GEICAM9906 trials [31]: luminal B tumors
were defined as HR-positive/HER2-negative/Ki67-posi-
tive or HR-positive/HER2-positive (N = 206, 21%), and
HER2-overexpressing tumors as HR-negative/HER2-
positive (N = 86, 9%). Luminal A and triple-negative
subtypes were not changed. As shown in Additional file
9, Table S7, unadjusted and adjusted HR for relapse
were very similar to previous analysis regarding the ben-
efit of docetaxel per subtype, with more benefit in the
luminal B and HER2-overexpressing subtypes, and no
benefit in the luminal A subtype..
Our study presents several strengths (randomized pro-
spective trial, high number of samples representative of
the whole trial population and of tested proteins, includ-
ing novel markers), but, like retrospective subset bio-
marker studies reported in adjuvant trials, suffers also
from several limitations: a relatively small number of
analyzed markers when compared with high-throughput
profiling of frozen samples, a relatively limited propor-
tion of available samples (55%), and limitations intrinsic
to unplanned analyses. The relatively low number of
events and the relatively small benefit of the experimen-
tal arm (HR = 0.81) make the study not powered
enough to detect small interactions between markers
and docetaxel benefit. The PACS01 trial, like other
trials, was not designed to detect the benefit of taxanes
in patient subgroups defined by markers. Conversely,
unplanned analyses confer a risk of false positive results.
For both reasons, meta-analysis of first-generation tax-
ane trials incorporating molecular data, ideally centrally
generated, is warranted in the context of international
collaborations (planned future EBCTCG meta-analysis),
as well as validation in ongoing second-generation tax-
ane trials. For example, a validation study is planned to
test the predictive value of Ki67 in the PACS04 trial,
which compared three cycles of FEC three of docetaxel
vs. six of ED (Epirubicine Docetaxel).
Other limitations are methodological (IHC) and con-
ceptual (breast cancer heterogeneity). Breast cancer is
heterogeneous. Given the extent of differences between
the four molecular subtypes (luminal A and B, HER2-
overexpressing, and triple-negative), and because a sig-
nal relevant in a given subtype may be diluted and
undetectable in the whole population, and conversely a
signal relevant in the whole population may not be
detected in a given subtype, another promising approach
is to redefine prognostic and predictive markers in each
subtype [52]. Results of univariate prognostic analyses
are detailed in Additional file 10, Table S8, showing, for
example, that the negativity of BCL2, EGFR, and TAU
were significant prognosticators in the luminal A sub-
type, but not in the other subtypes, or that TACC2-
positivity had an unfavorable prognostic value in the
HER2-overexpressing subtype, but favorable in the tri-
ple-negative subtype. However, given the relatively small
size of each subtype in our series, this deserves to be
reassessed in a larger series and in multivariate analysis.
Regarding IHC, it is known to be non-quantitative, and
it is difficult to know the most biologically relevant cut-
offs for prognostic and predictive analyses. In the present
study, all cut-offs were predefined before statistical ana-
lyses. For ER, PR and HER2, we used the Saint-Gallen cut-
offs [53]. For the other proteins, the challenge is more sub-
stantial. For Ki67, important guidelines are under develop-
ment [42,54-57]. A meta-analysis of 46 studies published
in 2007 reported many different Ki67 cut-offs, ranging
from 3.5% to 34% [35]. The 2011 Saint-Gallen cut-off has
been fixed at 14%, based on comparison with gene array
data (PAM50) as a prognostic factor [54]. However, as sta-
ted in the recommendations [53], the “optimal cut-points
in Ki67 labeling index for prediction of efficacy of endo-
crine or cytotoxic therapy may vary”. Here, to remain con-
sistent with our previous PACS01 sub-study [30], we used
a 20% cut-off. For the other 30 tested proteins, and in the
absence of consensual guidelines, we used a 1% cut-off.
We are aware that the chosen cut-offs may not be optimal
in terms of prognostic and/or predictive values. We have
thus planned the analysis of different cut-offs for each pro-
tein, which will require identification and validation in
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value of Ki67 and its value predictive for docetaxel benefit
remained significant in multivariate analysis when we
applied a 15% cut-off (data not shown), regardless of the
cut-off for ER and PR: 1% (P = 0.028 and P for interaction
= 0.033 respectively) or 10% (P = 0.022 and P for interac-
tion = 0.031 respectively). By contrast, the favorable
impact of the luminal B subtype for the docetaxel benefit
lost its significance (P-value for interaction = 0.208 in mul-
tivariate analysis) when we used a 15% cut-off for Ki67
(Additional file 11, Table S9). Another analytic approach
is to study the prognostic and predictive values of continu-
ous IHC variables. As a preliminary approach, we used
quartiles of IHC measurements to categorize our popula-
tion (percent of stained tumor cells for the data generated
on standard slides and quick score QS for the TMA data;
Additional file 12, Table S10). We then assessed for each
protein the magnitude of the prognostic and treatment
effects as a function of such categorization. The results of
multivariate analyses (Additional file 13, Table S11)
showed a differential DFS according to the value of Ki67
and PR, with a maximum difference for the highest quar-
tile (effect unfavorable for Ki67 and favorable for PR).
There was also a trend towards a differential benefit of
docetaxel versus no docetaxel according to the value of
Ki67 and Aurora A, with a maximum benefit for the high-
est quartile for both proliferation markers (Additional file
14, Table S12). Complementary analyses, such as STEPP
analysis (subpopulation treatment effect pattern plot) [58],
are warranted.
Conclusions
We confirm that ER, PR or HER2 status alone does not
predict the benefit of docetaxel as adjuvant therapy in
node-positive early breast cancer patients treated with
anthracycline-based chemotherapy. We show that Ki67
status alone may be informative. We show also that the
molecular subclassification may predict which patient
may not benefit from docetaxel (luminal A) and may
benefit more than the unselected population (luminal B,
HER2-overexpressing), but does not provide additional
information to Ki67 status al o n e .T og of u r t h e ri na n a -
lyses, a supervised analysis [33] will be applied to our
dataset, using semi-quantitative and quantitative data, to
attempt identifying a multiprotein predictor for doce-
taxel benefit, overall and per subtype.
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